Summers Healthcare, Llc | |
119 North 6th Street, Okeene, Oklahoma 73763 | |
(580) 822-4441 | |
Name | Summers Healthcare, Llc |
---|---|
Location | 119 North 6th Street, Okeene, Oklahoma |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 48 |
Occupancy Rate | 51.67% |
Medicare ID (CCN) | 375478 |
Legal Business Name | Summers Health Services, Llc |
Ownership Type | For Profit - Individual |
NPI Number | 1114220191 |
Organization Name | SUMMIT HEALTHCARE RECEIVERSHIP LLC |
Address | 119 N. 6th, Okeene, OK 73763 |
Phone Number | 580-822-4441 |
News Archive
Antigenics today announced that the Brain Tumor Research Center at the University of California, San Francisco (UCSF), has presented an update on a Phase 2 clinical trial of Oncophage (vitespen) for recurrent high grade glioma (brain cancer) at the 2009 Joint Meeting of SNO (Society for Neuro-Oncology) and AANS/CNS Section on Tumors 2009 in New Orleans, LA.
NicOx S.A. today announced that a Marketing Authorization Application (MAA) for naproxcinod has been submitted to the European Medicines Agency (EMEA) through the centralized procedure, seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA).
Dr. Gregory Bix, Paul G. Blazer J. Professor of Stroke Research in the University of Kentucky Sanders-Brown Center on Aging and the UK departments of Anatomy and Neurobiology and Neurology, has received funding of $224,416 from the National Institutes of Health, to further study of stroke recovery.
According to a major Swedish cohort study from researchers at Karolinska Institutet in Sweden and Imperial College London, a surgeon who operates on oesophageal cancer must have performed 60 operations to prevent any lack of experience adversely affecting the long-term survival of the patients. The finding, which is published in the Journal of Clinical Oncology, has potential significance for clinical practice.
› Verified 1 days ago
NPI Number | 1467843177 |
Organization Name | SUMMERS HEALTH SERVICES, LLC |
Address | 119 N. 6th St, Okeene, OK 73763 |
Phone Number | 580-822-4441 |
News Archive
Antigenics today announced that the Brain Tumor Research Center at the University of California, San Francisco (UCSF), has presented an update on a Phase 2 clinical trial of Oncophage (vitespen) for recurrent high grade glioma (brain cancer) at the 2009 Joint Meeting of SNO (Society for Neuro-Oncology) and AANS/CNS Section on Tumors 2009 in New Orleans, LA.
NicOx S.A. today announced that a Marketing Authorization Application (MAA) for naproxcinod has been submitted to the European Medicines Agency (EMEA) through the centralized procedure, seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA).
Dr. Gregory Bix, Paul G. Blazer J. Professor of Stroke Research in the University of Kentucky Sanders-Brown Center on Aging and the UK departments of Anatomy and Neurobiology and Neurology, has received funding of $224,416 from the National Institutes of Health, to further study of stroke recovery.
According to a major Swedish cohort study from researchers at Karolinska Institutet in Sweden and Imperial College London, a surgeon who operates on oesophageal cancer must have performed 60 operations to prevent any lack of experience adversely affecting the long-term survival of the patients. The finding, which is published in the Journal of Clinical Oncology, has potential significance for clinical practice.
› Verified 1 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
Antigenics today announced that the Brain Tumor Research Center at the University of California, San Francisco (UCSF), has presented an update on a Phase 2 clinical trial of Oncophage (vitespen) for recurrent high grade glioma (brain cancer) at the 2009 Joint Meeting of SNO (Society for Neuro-Oncology) and AANS/CNS Section on Tumors 2009 in New Orleans, LA.
NicOx S.A. today announced that a Marketing Authorization Application (MAA) for naproxcinod has been submitted to the European Medicines Agency (EMEA) through the centralized procedure, seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA).
Dr. Gregory Bix, Paul G. Blazer J. Professor of Stroke Research in the University of Kentucky Sanders-Brown Center on Aging and the UK departments of Anatomy and Neurobiology and Neurology, has received funding of $224,416 from the National Institutes of Health, to further study of stroke recovery.
According to a major Swedish cohort study from researchers at Karolinska Institutet in Sweden and Imperial College London, a surgeon who operates on oesophageal cancer must have performed 60 operations to prevent any lack of experience adversely affecting the long-term survival of the patients. The finding, which is published in the Journal of Clinical Oncology, has potential significance for clinical practice.
› Verified 1 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 1 |
Total Amount of Fines in Dollars | $650 |
Number of Payment Denials | 0 |
Total Number of Penalties | 1 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 9.09 | 14.46 |
Percentage of long-stay residents who lose too much weight | 4.85 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 53.49 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 4.46 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 1.09 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 3.57 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 15.15 | 14.2 |